Please assess the completion status of the following clinical trial:

Trial Title: Mayo Acute Stroke Trial for Enhancing Recovery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Definite or probable acute ischemic cerebrovascular syndrome (AICS), as defined by Kidwell et al (Stroke. 2003;34:2995-8).~* Experimental treatment started within 24 hours of onset of symptoms.~* Age ≥ 18 years.~* Ability and willingness to return for follow-up visits.~* Willingness of an available informant who knows the patient well to participate in informant-based questionnaires for the duration of the follow-up period.~* Living in independent or semi-independent living situation before the stroke.~* Fluent in English before the stroke.~* Provides written informed consent.~* Near visual acuity of at least 20/200 in at least one eye.~* Auditory acuity of at least having the ability to detect finger rubbing in at least one ear.~Exclusion Criteria:~* Parkinson's disease or restless leg syndrome.~* Partial or generalized seizures.~* No acute decompensated heart failure~* Routinely requiring daytime supplemental oxygen before the stroke; study participants on continuous positive air pressure (CPAP) for obstructive sleep apnea remain eligible.~* Gastrointestinal or genitourinary surgery within 1 month of screening.~* Gastrointestinal bleeding.~* Syncope or symptomatic bradycardia.~* Creatinine ≥ 3.5 mg/dL or requiring dialysis.~* Peptic ulcer disease.~* Asthma.~* Tracheostomy or endotracheal intubation.~* Taking donepezil or other acetylcholinesterase inhibitor at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Donepezil (Type: EXPERIMENTAL): Participants received treatment with donepezil within 24 hours after the onset of ischemic stroke symptoms. Participants received donepezil 5 mg/day for 30 days, followed by an increase to 10 mg/day for 60 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).